Best Neurology Companies in Minnesota, United States
The 32 best Neurology companies in Minnesota, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Saluda Medical.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Minnesota
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Saluda Medical Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment 62Funding top 14%Moat top 31%News top 39%Growth top 42% All 8 signals ▾Fundingtop 14% Moattop 31% Newstop 39% Growthtop 42% Markettop 44% Techtop 45% Talentbottom 49% Globalbottom 43% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 62/100 | $400M | 12 mo ago | Public | Jim Schuermann CEO | 327 | WordPress Site EditorWordPressApple iCloud Mail+26 | — | — |
| 2 | Monteris Minimally invasive robotic laser thermotherapy 55Funding top 15%Moat top 31%Talent top 38%Market top 43% All 8 signals ▾Fundingtop 15% Moattop 31% Talenttop 38% Markettop 43% Growthtop 48% Newsbottom 42% Techbottom 38% Globalbottom 37% Funding: Raised $174M across 20 rounds · 20 rounds over 18 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $174M | 7 mo ago | Series E | Richard Tyc Co-Founder & SVP Science & Technology | 100 100 → 128 (+28%) | — | — | — |
| 3 | ShiraTronics Developer of a neuromodulating device for treating migraine | $108M | 25 mo ago | Series B | — | 29 | WordPress Block EditorBeaver BuilderWordPress+15 | 67 patents Implantable cranial neurostimulation devices with wireless charging and thermal management | — |
| 4 | CoAxia Catheter-based treatment for cerebral ischemia | $73M | 188 mo ago | Acqui-Hired | Joyce Wahr Managing Director | 20 | — | 23 patents Partial aortic occlusion and flow‑reversal devices for cerebral perfusion augmentation and emboli prevention | — |
| 5 | MIVI Neuroscience Developer of catheters for acute ischemic stroke therapy | $66M | 39 mo ago | Series C | — | 37 | — | 98 patents Neurovascular aspiration and thrombectomy catheters with embolic protection for cerebral vessels | — |
| 6 | iVEAcare Developer of neuromodulation technology intended to treat patients suffering from chronic diseases | $28M | 30 mo ago | Series A | Mudit Jain Co-Founder | — | — | 5 patents Personalized vagus nerve stimulation and AI-driven seizure/depression monitoring systems | — |
| 7 | Veravas Provider of platform to manage sample preparation and diagnostic solutions | $25M | 31 mo ago | Series A | John Forrest Founder and Executive Chairman | 4 | WordPressMySQLPHP+23 | 51 patents Multiplex biomarker detection and enrichment platforms for clinical diagnostic assays | — |
| 8 | Minnetronix Medical Manufacturer of multiple devices for neurocritical patients | $20M | 72 mo ago | Acquired | Rich Nazarian Retired Founder and CEO Minnetronix Medical | 263 | — | — | — |
| 9 | RxFunction Provider of wearable prosthesis for people with sensory peripheral neuropathy | $19M | 48 mo ago | Series B | Lars Oddsson CTO & Co-Founder | 30 | WordPressApple iCloud MailMicrosoft 365+23 | 26 patents Wearable sensory feedback systems for gait and balance rehabilitation in prosthetics | — |
| 10 | Hyloris Developer of drugs for rare and orphan disease conditions | $16M | 78 mo ago | Public | Stijn Rompay CEO | 14 | WordPressMySQLPHP+17 | — | — |
| 11 | Alpheus Medical Developer of Sonodynamic therapy device for brain cancer | $16M | 18 mo ago | Series B | Vijay Agarwal Founder & CEO | 7 | — | — | — |
| 12 | CNS Therapeutics Intrathecal Baclofen in pre-filled syringes and vials | $13M | 166 mo ago | Acquired | Richard Penn Co-Founder & CSO | — | — | — | — |
| 13 | NeuroOne Developer of AI-enabled diagnostic and treatment devices for neurological diseases | $13M | 69 mo ago | Public | — | 15 | — | 5 patents Intracranial neural probe devices for electrophysiology recording and targeted drug delivery | — |
| 14 | SpineThera Developer of injectable drugs for back pain | $12M | 54 mo ago | Acquired | Jeff Missling Founder & CEO | 6 | — | 27 patents Patents concentrated in health & consumer products | — |
| 15 | Orasi Medical Provider of imaging software to diagnose and monitor neurological diseases | $5M | 191 mo ago | Deadpooled | Mark T. Wagner CEO | — | — | — | — |
| 16 | Inspired Life Medical Developer of screening tools for Alzheimer's disease | $3M | 75 mo ago | Seed | David Wagner Founder & CEO | — | — | — | — |
| 17 | Surgical Information Sciences AI and cloud-based platform for visualizing brain MRI images | $3M | 84 mo ago | Seed | Guillermo Sapiro Co-Founder | — | — | — | — |
| 18 | Sora Neuroscience Developer of brain mapping software utilizing resting state functional MRI | $1M | 36 mo ago | Seed | — | 3 | — | — | — |
| 19 | VitalMedix Develop drug to treat hemorrhagic shock or severe ischemia/hypoxia | $1M | 206 mo ago | Deadpooled | Jeffrey M. Williams CEO | — | — | — | — |
| 20 | Lumen Biomedical Interventional devices for embolic protection and thrombus removal | $675K | 204 mo ago | Deadpooled | Steven Healy CEO | — | — | 49 patents Intravascular embolic filtration catheters for cardiac valve and carotid artery protection | — |
Top 12 Neurology companies in Minnesota
#1
Series E · Plymouth, Minnesota · founded 1999 · 100 employees$174.3Mraised▾
Monteris Medical is focused on providing innovative MRI-guided neurosurgical ablation tools and solutions for neurosurgeons. By combining the imaging power of Magnetic Resonance Imaging (MRI), advanced navigation software and Laser Interstitial Thermal Therapy (LITT), Monteris Medical has created a system to reach virtually any area of the brain.
- Mar 2026Series E$28M
- Mar 2026Conventional Debt$35M
- Oct 2022Conventional Debt$38M
- Oct 2022Series D$35M
#2
Public · Bloomington, Minnesota · founded 2010 · 327 employees$400Mraised▾
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment. It offers a system that measures and records neural activation characteristics. The system quantifies stimulation levels to a clinician-defined target, continuously comparing neural activation with the target level. It automatically adjusts stimulation current to ensure consistent neural activation. The company focuses on neuromodulation solutions for chronic pain. It utilizes Evoked Compound Action Potentials to advance neuromodulation therapy.
- Oct 2025Series F$30M
- Jan 2025Series F$100M
- Apr 2023Series F$150M
- Mar 2022Series F$125M
#3
Series B · Chanhassen, Minnesota · founded 2014 · 7 employees$16Mraised▾
Developer of Sonodynamic therapy device for brain cancer. It offers a proprietary non-invasive treatment device that utilizes ultrasound to activate a drug targeting cancer cells for outpatient treatment of recurrent glioblastoma multiforme and selectively target and kill cancer cells.
- May 2025Series B$52M
- Nov 2021Series A$16M
#4
Series B · Minneapolis, Minnesota · founded 2019 · 29 employees$107.7Mraised▾
ShiraTronics (a spinout from NuXcel) is a developer of neuromodulation devices for treating migraines. The company claims that the implant uses neuromodulation technologies to treat migraine and other chronic diseases. Some of the partners are AMZAK, APERTURE, and LivaNova.
- Sep 2024Series B$66M
- Aug 2023Series A$8.7M
- Nov 2019Series A$33M
#5
Series C · Eden Prairie, Minnesota · founded 2013 · 37 employees$66Mraised▾
MIVI Neuroscience is a developer of solutions for acute ischemic stroke (AIS). The company's proprietary technology is designed in collaboration with physicians to improve the safety and efficacy of interventional AIS therapy. The platform is designed to enhance neurovascular access, revascularization, and protection during interventional neuroradiology (INR) procedures.
- Jul 2023Series C$10M
- Jan 2021Series B—
- Dec 2020Series B$45M
- Mar 2020Series A$2.2M
#6
Series A · Minneapolis, Minnesota · founded 2023$27.5Mraised▾
Developer of neuromodulation technology intended to treat patients suffering from chronic diseases. It offer devices and software that deliver targeted electrical stimulation to specific areas of the brain or spinal cord enabling medical professionals to create therapies.
- Apr 2024Series A$27.5M
#7
Series A · Oakdale, Minnesota · founded 2017 · 4 employees$25Mraised▾
VERAVAS provides a platform to manage sample preparation and diagnostic samples. The proprietary technology VeraPrep which helps in optimizing the patient's samples and preparing it for the diagnostic process by eliminating biotin and multiple interference substances using nanobead technology. The processed samples are then analyzed using VeraTest platform which detects the biomarkers attached with the nanobeads to identify the type of diseases.
- Mar 2024Conventional Debt—
- Mar 2024Series A$20.6M
- Feb 2020Seed$4M
- Oct 2019Seed$375K
#8
Seed · Excelsior, Minnesota · founded 2021$25Kraised▾
Developer of medical devices for the treatment of neurodegenerative diseases. The company is focused on developing proprietary technologies to improve brain health with bioelectronic solutions that enhance glymphatic system function.
- Dec 2025Seed—
- Jun 2024Seed$25K
#9
Series B · Minneapolis, Minnesota · founded 2010 · 30 employees$19.4Mraised▾
RxFunction provides wearable prostheses for people with sensory peripheral neuropathy. It develops advanced balance technology solutions, aiming to aid patients with loss of balance. The product consists of a leg unit and a footpad (insoles). The product's insoles measure the patient's foot pressure and provide real-time tactile sensory cues to help control balance and stability. The leg unit wraps around the lower leg of the user and contains electronics for reading the insole signals, a microprocessor as well as four vibrating motors that provide tactile sensory cues to the user.
- Oct 2022Series B$5M
- Jan 2021Series A$292.4K
- Dec 2020Series A$4M
- Mar 2020Series A$4M
#10
Acqui-Hired · Maple Grove, Minnesota · founded 1999 · 20 employees$72.6Mraised▾
CoAxia was developing catheter-based perfusion augmentation therapies to improve outcomes for patients with cerebral ischemia. The core application for CoAxia’s catheter technology, under the trade names NeuroFlo and FloControl, involves the redistribution of blood flow from the lower extremities to support brain function during ischemia. Acquired by Zoll, an Asahi Kasei Group company in 2013.
- Mar 2011Series D$22.5M
- Jun 2009Series D$21.5M
- Sep 2006Series C$11M
- 2004Series B$17.6M
#11
Acquired · Plymouth, Minnesota · founded 2012 · 6 employees$11.5Mraised▾
Developer of injectable drugs for back pain. The company's lead candidate utilizes patent-protected sustained-release drug-delivery technology which is an anti-inflammatory steroid to reduce frequent epidural injections for back pain.
- Apr 2022Grant (prize money)$5M
- Jun 2021Series A$1.2M
- Jun 2021Conventional Debt—
- Nov 2018Series A$2M
#12
Acquired · Saint Paul, Minnesota · founded 1996 · 263 employees$20Mraised▾
Manufacturer of multiple devices for neurocritical patients. The products provided are spinal cord stimulation devices for chronic pain, urinary incontinence, muscle stimulation, peripheral nerve, intracranial stimulation, and others. It also provides endoscopic imaging systems and test equipment. The company is developing a portfolio of solutions designed to prevent secondary injury and enhance healing for patients. It also developed optical systems that create algorithms for image processing and display to optimize sensor performance and visualization. It provides thermal simulation and modeling techniques that help in electroporation and trans-cellular pharmaceutical delivery. The platform offers neurapheresis therapies for the treatment and return of cerebrospinal fluid.
- Oct 2020Grant (prize money)—
- Aug 2019Grant (prize money)$2.5M
- Sep 2016Grant (prize money)$1.6M
- Sep 2016Grant (prize money)$1.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neurotech in Minnesota is moving
A read on the academic research around Neurotech in Minnesota — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 247 papers.
- University of Minnesota218
- University of Minnesota System24
- University of Minnesota Medical Center18
- University of Minnesota Rochester3
- University of Minnesota, Waseca2
- Neuroscience6→13
- Deep brain stimulation12→17
- Local field potential1→5
- Stimulation2→6
- Neuromodulation2→5
- Deep brain stimulation31→40
- Neuromodulation1→9
- Stimulation9→16
- Brain stimulation1→8
- Physical medicine and rehabilitation1→6
- Neuromodulation1→5
- Parkinson's disease3→5
- Disease1→3
- Deep brain stimulation15→16
- Brain stimulation2→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.